Affordable Access

deepdyve-link
Publisher Website

Fusion of the Genes WWTR1 and FOSB in Pseudomyogenic Hemangioendothelioma.

Authors
  • Panagopoulos, Ioannis1
  • Lobmaier, Ingvild2
  • Gorunova, Ludmila3
  • Heim, Sverre3, 4
  • 1 Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway [email protected] , (Norway)
  • 2 Department of Pathology, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. , (Norway)
  • 3 Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. , (Norway)
  • 4 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. , (Norway)
Type
Published Article
Journal
Cancer Genomics & Proteomics
Publisher
International Institute of Anticancer Research
Publication Date
Jan 01, 2019
Volume
16
Issue
4
Pages
293–298
Identifiers
DOI: 10.21873/cgp.20134
PMID: 31243110
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Pseudomyogenic hemangioendothelioma is a rare endothelial tumor. Previous genetic investigations have shown that the tumors carry either a SERPINE1-FOSB or an ACTB-FOSB fusion gene. The aim of the study was to identify FOSB fusions linked with pseudomyogenic hemangioendothelioma. RNA sequencing, reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing analyses were performed on a pseudomyogenic hemangioendothelioma. An in-frame fusion was found between exon 4 of WWTR1 from 3q25 and exon 2 of FOSB from 19q13. The fusion gene not only places FOSB under the control of the WWTR1 promoter, but is predicted to encode a chimeric WWTR1-FOSB transcription factor. FOSB may be fused with SERPINE1, ACTB, or WWTR1 in pseudomyogenic hemangioendotheliomas. The resulting overexpression of FOSB fusion is a potentially useful marker that could be helpful in the diagnosis of these tumors. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Report this publication

Statistics

Seen <100 times